William Blair analyst Ryan Daniels has maintained their bullish stance on HNGE stock, giving a Buy rating on December 11.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ryan Daniels’s rating is based on his view that Hinge Health’s core financial outlook into 2026 remains solid despite modest adjustments to the timing and level of expenses. He maintains confidence in the company’s ability to deliver strong top-line growth, with his revenue expectations for 2026 essentially unchanged, and he continues to see meaningful profitability on a non-GAAP basis even after incorporating higher near-term operating costs.
At the same time, Daniels believes the company will generate healthy free cash flow in 2026, with only minor revisions needed to align with anticipated seasonality. In his analysis, the decision to pull some SG&A and R&D spending into the first half of 2026 represents a tactical shift rather than a deterioration in the long-term earnings and cash generation profile. Taken together, the sustained profit outlook, robust cash flow projections, and only modest estimate tweaks underpin his conviction that Hinge Health’s shares remain attractive, supporting his Buy rating.
According to TipRanks, Daniels is a 3-star analyst with an average return of 4.4% and a 44.38% success rate. Daniels covers the Healthcare sector, focusing on stocks such as TransMedics Group, Addus Homecare, and Idexx Laboratories.